These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 14611747)

  • 1. Proteinuria in diabetic nephropathy: treatment and evolution.
    Campbell RC; Ruggenenti P; Remuzzi G
    Curr Diab Rep; 2003 Dec; 3(6):497-504. PubMed ID: 14611747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction: nature of microalbuminuria, proteinuria, and progressive renal disease.
    Mogensen CE
    J Diabetes Complications; 1995; 9(1):2-6. PubMed ID: 7734738
    [No Abstract]   [Full Text] [Related]  

  • 3. Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: focus on hypertension and proteinuria.
    Lee GS
    Ann Acad Med Singap; 2005 Jan; 34(1):24-30. PubMed ID: 15726216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
    Ruggenenti P; Cravedi P; Remuzzi G
    Nat Rev Nephrol; 2010 Jun; 6(6):319-30. PubMed ID: 20440277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic nephropathy: pathogenetic basis for treatment.
    Reasner CA; DeFronzo R
    Contemp Intern Med; 1994 Oct; 6(10):30-2, 35-40. PubMed ID: 10150289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
    Kim MJ; Song JH; Suh JH; Lee SW; Kim GA
    Yonsei Med J; 2003 Jun; 44(3):463-72. PubMed ID: 12833584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does antihypertensive treatment prevent progression of microalbuminuria to overt proteinuria in insulin-dependent diabetic patients?
    Passa P
    J Am Soc Nephrol; 1992 Oct; 3(4 Suppl):S91-6. PubMed ID: 1457766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nephroprotection in young type 1 diabetic patients treated with converting enzyme inhibitor].
    Benamar L; Laboudi A; Rhou H; Laouad I; Fahi Z; Bentata Y; Amar Y; Ezzaïtouni F; Ouzeddoun N; Bayahia R; Balafrej L; Touzani A; Benhamou B; Balafrej A; Guedira A
    Presse Med; 2003 Apr; 32(14):638-43. PubMed ID: 12714902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of diabetic nephropathy.
    Materson BJ; Preston RA
    Hosp Pract (1995); 1997 Feb; 32(2):129-34, 139-40. PubMed ID: 9040425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinuria and progression of renal disease: therapeutic implications.
    Gansevoort RT; Navis GJ; Wapstra FH; de Jong PE; de Zeeuw D
    Curr Opin Nephrol Hypertens; 1997 Mar; 6(2):133-40. PubMed ID: 9146974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT; Ribeiro AB
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antiproteinuric effects of blood pressure-lowering agents: differences between nondiabetics and diabetics.
    de Jong PE; Heeg JE; Apperloo AJ; de Zeeuw D
    J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S28-32. PubMed ID: 1382162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases.
    Mimran A; Ribstein J
    Am J Hypertens; 1994 Sep; 7(9 Pt 2):73S-81S. PubMed ID: 7818839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprophylaxis of diabetic nephropathy in the elderly.
    Jungmann E
    Drugs Aging; 1996 Dec; 9(6):449-57. PubMed ID: 8972244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.